Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
was initiated with an Outperform rating and $410 price target at Robert Baird. Company should continue to gain market share.
was downgraded from Buy to Neutral at UBS. Valuation call, based on a $96 price target.
was downgraded from Buy to Neutral at Ticonderoga Securities. Stock is already pricing in recent market share gains.
was started with a Buy rating at Goldman Sachs. $81 price target. Company was also added to the Conviction List, based on the growth potential of Soliris.
was started with a Sell rating at Goldman Sachs. $50 price target. Denosumab will carry high prices but offer relatively little benefit.
Amgen was downgraded from Outperform to Market Perform at Leerink Swann. Investors should exercise more caution ahead of the company's upcoming binary events.
was upgraded to Neutral at Merriman, Curhan Ford. Company should benefit from improving capital markets.
was initiated with a Sell rating at Goldman Sachs. $50 price target. Company faces increased competition in the MS market.
was downgraded from Outperform to Sector Perform at RBC Capital. $18 price target. Company is seeing lower new student growth.
was downgraded from Outperform to Sector Perform at RBC Capital. $30 price target. Company continues to spend.
was downgraded from Buy to Hold at Jefferies. Company is running out of room to cut costs. $45 price target.
was downgraded to Market Perform from Market Outperform at JPM Securities. Maintain $25 price target.
was downgraded from Outperform to Market Perform at Barrington Research. Valuation call.
was upgraded from Sell to Neutral at MKM Partners. $88 price target. Stock appears attractively valued, following the recent pullback.
Fresh Del Monte
was downgraded from Buy to Hold at Jefferies. $23 price target. Banana market has deteriorated.
was downgraded from Overweight to Equal-Weight at Morgan Stanley. Valuation call.
Jones Lang Lasalle
was upgraded from Neutral to Buy at Goldman Sachs. Stock is attractively valued, following a post-earnings pullback. $88 price target.
was downgraded to Market Perform from Outperform at BMO Capital Markets. Tougher comps coming, BMO Capital Markets said. Maintain $85 price target.
estimates changed at Barclays. 2010 EPS estimate increased to $3.40, 2011 trimmed to $3.90. Disappointing Droshky performance, Barclays said. Maintain Equal Weight rating and $36 price target.
Marathon Oil numbers were reduced through 2015 at Goldman Sachs. Company seeing lower production in the Gulf of Mexico. Neutral rating and new $35 price target.
Marathon Oil downgraded from Buy to Hold at Deutsche Bank. $36 price target. The company's Droshky project is not meeting expectations.
was upgraded from Sector Perform to Outperform at RBC Capital. $86 price target. WL acquisition should help the company grow.
was downgraded from Sector Perform to Underperform at RBC Capital. $63 price target. Company lacks near-term catalysts.
was downgraded from Buy to Hold at Dahlman Rose. Valuation call.
Research In Motion
was started with a Market Perform rating at Wells Fargo. Stock is already pricing in bad news, but lacks near-term catalysts.
was downgraded from Buy to Neutral at UBS. $430 price target. Estimates also cut, as Kaplan faces regulatory problems.
was downgraded from Buy to Hold at Brean Murray. Company faces difficult comparisons in the coming quarters.
was downgraded to Neutral from Buy at Stern Agee. Concerned that the Macau market overall moves more toward Cotai, Stern Agee said. Price target set at $109.
was downgraded from Buy to Neutral at UBS. Valuation call, based on a $22 price target.
was upgraded from Neutral to Buy at Ticonderoga Securities. $34 price target. Company is losing market share, but the risk/reward is attractive at current levels.
This article was written by a staff member of TheStreet.